Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06291727 · ClinicalTrials.gov registry record · Phase 4
Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA
A Phase 4 study, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- Phase 4
- Development phase
- 138
- Enrollment target
NCT06291727: Completed Phase 4 study, sponsored by Prisma Health-Upstate.
NCT06291727 is a Phase 4 study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 138 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06291727, a Phase 4 study, has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 138 participants
- Enrollment target
Study Summary
This study is a prospective, double-blind prospective randomized controlled trial comparing mepivacaine and bupivacaine spinal anesthesia for same-day discharge readiness following a unilateral primary elective TKA procedure. Study data will be collected during the patient's hospital stay for their TKA procedure, and the primary outcome of same-day discharge readiness will be assessed the day of surgery. Patients will also be contacted at Day 3 post-op to assess for any complications, current level of pain, and pain medication utilization.
Primary Outcome
Whether a patient is discharged the same day their surgery occurred, or if they were required to stay overnight following surgery.
Interventions
- DRUG Bupivacaine
- DRUG Mepivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 4 |
What the finished NCT06291727 record still lists
NCT06291727 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT06291727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06291727 about?
NCT06291727 is a clinical study titled "Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA". This study is a prospective, double-blind prospective randomized controlled trial comparing mepivacaine and bupivacaine spinal anesthesia for same-day discharge readiness following a unilateral primary elective TKA procedure. Study data will be collected during the patient's hospital stay for their...
What is the current status of trial NCT06291727?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 138 participants. The study started on 2024-02-16. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT06291727?
The interventions under investigation include: Bupivacaine (DRUG), Mepivacaine (DRUG).
Who is sponsoring clinical trial NCT06291727?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06291727's enrollment target sits among peer trials
138 593rd of 2000 higher than 1,407 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI